Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fosphenytoin→

Fosphenytoin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
93390-81-9
Molecular formula
C16H15N2O6P
Molecular weight
362.27 g/mol
Drug class
Phenytoin prodrughydantoin antiseizure medicine
Mechanism of action
Fosphenytoin is rapidly converted to phenytoin. Phenytoin stabilises neuronal membranes by prolonging the inactivated state of voltage-gated sodium channels, limiting sustained high-frequency neuronal firing.
Indications / reported uses
  • Control of generalised tonic-clonic status epilepticus
  • Prevention and treatment of seizures occurring during neurosurgery
  • Short-term substitution for oral phenytoin when oral administration is not possible; route and loading dose are product-specific

Sources: US DailyMed — CEREBYX (fosphenytoin) · NLM MeSH — Fosphenytoin · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Phenytoin prodrug; hydantoin antiseizure medicine

Mechanism of action

Fosphenytoin is rapidly converted to phenytoin. Phenytoin stabilises neuronal membranes by prolonging the inactivated state of voltage-gated sodium channels, limiting sustained high-frequency neuronal firing.

General use cases

  • Control of generalised tonic-clonic status epilepticus
  • Prevention and treatment of seizures occurring during neurosurgery
  • Short-term substitution for oral phenytoin when oral administration is not possible; route and loading dose are product-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Fosphenytoin Environmental Risk Assessment (ERA) (the Fosphenytoin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.